Dr. Knackstedt, who was not involved in the study, says that the importance of nail health and the management of nail disease are often neglected or seen as an afterthought.
“Tofacitinib will have clinical utility in managing patients with moderate-to-severe plaque psoriasis who also have nail involvement,” he says.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Reference
- Merola JF, Elewski B, Tatulych S, et al. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017 Apr 7. pii:S0190–9622(17)30147-0. doi:10.1016/j.jaad.2017.01.053. [Epub ahead of print]